Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma.

Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma. Haematologica. 2017 Oct 05;: Authors: Landmann E, Burkhardt B, Zimmermann M, Meyer U, Woessmann W, Klapper W, Wrobel G, Rosolen A, Pillon M, Escherich G, Attarbaschi A, Beishuizen A, Mellgren K, Wynn R, Ratei R, Plesa A, Schrappe M, Reiter A, Bergeron C, Patte C, Bertrand Y Abstract In the European Intergroup EURO-LB02 Trial, children and adolescents with lymphoblastic lymphoma underwent the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster protocol without prophylactic cranial radiotherapy. Primary aims were to test whether replacing prednisone with dexamethasone during induction increases EFS in the T-cell lymphoblastic lymphoma subgroup and whether therapy duration can be reduced from 24 to 18 months (factorial design, randomizations). These questions could not be answered due to premature closure of the trial. Here, we report on the secondary aims of the study: whether the results of study NHL-BFM90 are reproducible and the evaluation of disease features and prognostic factors. 319 patients (66 precursor B-cell LBL, 233 T-Cell LBL, 12 mixed phenotype, 8 not classifiable) were enrolled. In induction, 215 patients received prednisone and 104 patients received dexamethasone. Median follow-up was 6.8 (3.0-10.3) years. 5-year EFS was 82+/-2% (12 toxic deaths, 5 secondary malignancies, 43 non-response/relapse [centr...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research